System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Rachel M Layman is an expert in Oncology at The University of Texas MD Anderson Cancer Center (United States). As of October 2026, ScienceLeadR ranks Rachel M Layman in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Rachel M Layman has authored 181 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 6 of them ongoing. SLR score: 953 (community average: 125). How the SLR is computed.

LeadR Profile

Rachel M Layman The University of Texas MD Anderson Cancer Center United States
953 ScienceLeadR Reputation 953

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology - Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026
Source: PubMed

The University of Texas MD Anderson Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 181

Citations

Citations: 2 913 1st author: 13 Last author: 24 Unique author: 1

Main journals

Cancer Res 40
J Clin Oncol 29
ESMO Open 13
Clin Cancer Res 8
Breast Cancer Res Treat 7

Best Journals

J Clin Oncol 17
Ann Oncol 5
Lancet Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.
PMID 42926108 — fulvestrant, breast neoplasms, neoplasms, disease progression, breast, therapeutics		Ann Oncol Top journal20260
Reply to: When PIK3CA Wild-Type Becomes a Biomarker Blind Spot.
PMID 42854111 — biomarkers		J Clin Oncol Top journal20260
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.
PMID 42324670 — language, aromatase, aromatase inhibitors, breast neoplasms, neoplasms, breast		Future Oncol20260
Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary.
PMID 42324685 — language, aromatase, aromatase inhibitors, breast neoplasms, cardiovascular diseases, neoplasms, breast, therapeutics		Future Oncol20260
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
PMID 42241670 — fulvestrant, breast neoplasms, neoplasms, hormones, breast		J Clin Oncol Top journal20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 7
Phase 1/Phase 2 4
Phase 2 4
Phase 1 3
Phase 3 3

By status:

Completed 8
Active not recruiting 4
Recruiting 4
Terminated 4
Available 1

By type:

Interventional 16
Observational 4
Expanded Access 1

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 1
multicentric5to9 2
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Real life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164 — anastrozole, aromatase, aromatase inhibitors, breast neoplasms, pharmaceutical preparations, neoplasms, letrozole, breast, therapeutics		N/AActive not recruiting2024
Adding an Immunotherapy Drug MEDI4736 (Durvalumab) to the Usual Chemotherapy Treatment (Paclitaxel Cyclophosphamide and Doxorubicin) for Stage II III Breast Cancer
NCT06058377 — taxes, cells, research design, epidermal growth factor, quality of life, genetic testing, growth, blood, breast neoplasms, paclitaxel, pharmaceutical preparations, disulfides, cyclophosphamide, doxorubicin, neoplasms, mammography, drug therapy, immunoglobulins, hormones, immunotherapy, receptors, growth factor, breast, daunorubicin, specimen handling, therapeutics, tissues, immunoglobulin g, chemotherapy, carcinoma		Phase 3Recruiting2023
TRUDI TDXD Durva in HER2 Low IBC
NCT05795101 — breast neoplasms, pharmaceutical preparations, neoplasms, adenocarcinoma, inflammatory breast neoplasms, breast, trastuzumab		Phase 2Recruiting2023
Study of AC699 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative (ER HER2 ) Locally Advanced or Metastatic Breast Cancer
NCT05654532 — epidermal growth factor, estrogens, growth, safety, breast neoplasms, receptors, estrogen, neoplasms, receptors, growth factor, breast, pharmacokinetics		Phase 1Active not recruiting2022
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard of Care for the Treatment of Patients With Advanced or Metastatic HR HER2 Breast Cancer (VIKTORIA 1)
NCT05501886 — injections, fulvestrant, aromatase, aromatase inhibitors, breast neoplasms, neoplasms, tablets, neoplasm metastasis, breast, therapeutics		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS